BMRN – biomarin pharmaceutical inc. (US:NASDAQ)
Stock Stats
News
BioMarin Pharmaceuticals: Amicus Transforms Business Case Overnight [Seeking Alpha]
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target raised by analysts at Truist Financial Corporation from $80.00 to $100.00. They now have a "buy" rating on the stock.
A $4.8 Billion Reason to Buy BioMarin Stock Today [Yahoo! Finance]
BioMarin: Amicus Buyout Sparks My Enthusiasm [Seeking Alpha]
BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B [Yahoo! Finance]
Form 8-K BIOMARIN PHARMACEUTICAL For: Dec 19
Form 8-K BIOMARIN PHARMACEUTICAL For: Dec 19
Form 8-K BIOMARIN PHARMACEUTICAL For: Dec 11
Form 4 BIOMARIN PHARMACEUTICAL For: Dec 01 Filed by: Hardy Alexander
Form SCHEDULE 13G/A BIOMARIN PHARMACEUTICAL Filed by: VIKING GLOBAL INVESTORS LP
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.